Back to 2015 Annual Meeting Program

INTRODUCTION AND OBJECTIVES: Since our first publication in 2006, only 3 series have been published concerning the use of botulinum toxin in the treatment of OAB in non-neuropathic children (ona-BoNT, n=21 and 57; abo-BoNT, n=27). We present the results and side effects observed after the treatment of all non-neuropathic children, which have been treated in our institution between 2004 and 2014 (n=192), in order to define its place in the treatment of non-neurogenic OAB

METHODS: During the study period, 122 boys and 70 girls with a mean age of 9 years (+- 2,5) were treated with ona- BoNT-A. All patients were true therapy resistant, meaning that all previous therapies, both urotherapy and medical treatment, were unsuccessful. A standard dose of 100 IU was used in nearly all subjects. The injection was performed in 15 extratrigonal spots and without including the bladder dome. For the definition of success, the ICCS criteria were used, however, for enuresis it was adapted: full success 0 episodes/month, partial success <2 month.

RESULTS: In children with diurnal incontinence, 74% had a successful treatment (52% full response/response and 22% partial response). In patients presenting with enuresis, the successrate was lower: 49% (27% full success and 22% partial success). In 15 patients (8%) an UTI was reported as treatment related complication. Retention was not observed. No general side effects or severe adverse events were observed.

CONCLUSIONS: Onabotulinum toxin A is a safe and effective treatment for OAB in non-neuropathic children. It can be a useful treatment option for therapy resistant overactive bladder and/or nonmonosymptomatic enuresis.

Source of Funding: None